Genelux Corporation (GNLX) NASDAQ
2.99
+0.02(+0.67%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
2.99
+0.02(+0.67%)
Currency In USD
| Previous Close | 2.97 |
| Open | 2.97 |
| Day High | 3.03 |
| Day Low | 2.91 |
| 52-Week High | 8.54 |
| 52-Week Low | 2.29 |
| Volume | 126,763.29 |
| Average Volume | 184,133 |
| Market Cap | 112.47M |
| PE | -3.52 |
| EPS | -0.85 |
| Moving Average 50 Days | 2.73 |
| Moving Average 200 Days | 3.77 |
| Change | 0.02 |
Genelux Corporation to Participate in Upcoming Conferences
GlobeNewswire Inc.
Feb 18, 2026 1:00 PM GMT
WESTLAKE VILLAGE, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that the Company will participate in two upcoming conferences. Oppenheimer Healthcare Lif
Genelux Corporation Announces Upcoming Virtual Fireside Chat Hosted by Titan Partners
GlobeNewswire Inc.
Jan 12, 2026 9:00 PM GMT
WESTLAKE VILLAGE, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO and Chairman of the Board; Matt Pulisic, Chief Finan
Genelux Corporation Announces Pricing of $20.0 Million Underwritten Public Offering of Common Stock
GlobeNewswire Inc.
Jan 08, 2026 2:13 PM GMT
WESTLAKE VILLAGE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Genelux Corporation (“Genelux”) (Nasdaq: GNLX), a late clinical-stage immuno-oncology company, today announced the pricing of an underwritten public offering of 6,666,667 shares of its com